Join the 'Blepharospasm' group to help and get support from people like you.
Posted 18 Apr 2016 by Drugs.com
MONDAY, April 18, 2016 – Botox is a safe and effective treatment for chronic migraine and three other neurological disorders, an updated guideline from the American Academy of Neurology says. Long used to smooth wrinkles, botulinum toxin is made by a type of bacteria. The toxin blocks the release of substances at nerve endings, reducing muscle contraction and the transmission of pain signals, the researchers explained. The authors of the updated guideline reviewed scientific studies on the four preparations of botulinum toxin available in the United States. They concluded that the treatment is generally safe and effective for four neurological conditions: chronic migraine, spasticity in adults, cervical dystonia and blepharospasm. Chronic migraine is defined as having migraines 15 or more days a month, the study authors explained. Spasticity in adults is muscle tightness that ... Read more
Related support groups: Migraine, Migraine Prevention, Migraine Prophylaxis, Cervical Dystonia, Facial Wrinkles, Chronic Spasticity, Spasticity, Blepharospasm, Upper Limb Spasticity, Lower Limb Spasticity, Botulinum Toxin Type B, Myobloc, Spinal Spasticity
FDA Approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
Posted 2 Aug 2010 by Drugs.com
GREENSBORO, N.C., Aug. 2 /PRNewswire/ – Merz Pharmaceuticals today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S. "This is an important regulatory milestone for Xeomin and is key to establishing our neurology business in the U.S.," said Jack Britts, President and CEO of Merz Pharmaceuticals, LLC. "We at Merz understand, and are committed to, addressing the complexities of treating and living with these neurological disorders." The FDA approval of Xeomin is based on the results of two pivotal U.S. clinical trials ... Read more